Nicole R. Hadas, See Remarks at Akebia Therapeutics, Inc. (AKBA), bought 3,500 shares at $17.00 ($60K) on 2014-03-25, disclosed to the SEC on 2014-03-27.
Open-market purchase of $60k AKBA by See Remarks. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| AKBA | SELL | 2024-02-29 | $11K | — | Filing → |
| AKBA | SELL | 2023-05-25 | $154K | — | Filing → |
| AKBA | SELL | 2023-03-03 | $11K | — | Filing → |